Here's Why Ovid Therapeutics Stock Popped Higher Today | The Motley Fool
Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase 2.

Source: The Motley Fool
Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase 2.